ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: Simone Named New Director At St. Jude; Schein To Leave Georgetown For Job At Smith-Kline

September 16, 1983

Bill Introduced To Curb NIH Use Of Title 42 Salaries

August 10, 2012

RFA For Patient Compliance Study

September 26, 1980

A Conversation With Daniel Masys: Acronym “CABIG” Could Be Eliminated

January 6, 2012

NIH Director Collins Challenged On Capitol Hill Over NCI-Funded Research Linking Tea Party With Tobacco Companies

March 8, 2013

A Year in Houston: DePinho Reflects on Plans, Conflicts, Controversies—and Lessons Learned

September 7, 2012